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Canine mast cell tumours: a review of the pathogenesis, clinical
features, pathology and treatment
Abstract
Mast cells (MCs) are well known for their neoplastic transformation in solitary and multiple cutaneous
mast cell tumours (MCTs), as well as visceral and systemic mastocytosis. Dogs have an unique risk of
developing cutaneous MCTs, and they account for 7% to 21% of all canine skin tumours. The aetiology
of canine MCTs is unknown but is probably multi-factorial. This article reviews uptodate knowledge on
the pathogenesis, the clinical presentation, the clinical prognostic factors, the diagnostic workup
including clinical staging, cytological findings, histological findings and the various grading systems
which have been evaluated based on morphology, the assessment of proliferation markers and other
factors such as vessel density. Furthermore detailed information about current treatment protocols for
canine cutaneous MCTs are provided.  
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ABSTRACT 
Mast cells (MCs) are well known for their neoplastic transformation in solitary and multiple cutaneous 
mast cell tumours (MCTs), as well as visceral and systemic mastocytosis. Dogs have an unique risk of 
developing cutaneous MCTs, and they account for 7% to 21% of all canine skin tumours. The aetiology 
of canine MCTs is unknown but is probably multi-factorial. This article reviews uptodate knowledge on 
the pathogenesis, the clinical presentation, the clinical prognostic factors, the diagnostic workup including 
clinical staging, cytological findings, histological findings and the various grading systems which have 
been evaluated based on morphology, the assessment of proliferation markers and other factors such as 
vessel density. Furthermore detailed information about current treatment protocols for canine cutaneous 
MCTs are provided.   
 
INTRODUCTION 
Mast cells (MCs) are found in most organs and tissues of the body and are present in highest numbers in 
locations that interface with the environment, such as the skin, the lung and the gastrointestinal tract.1 It is 
estimated that if all MCs in the human body were assembled in one organ, their mass would equal that of 
the spleen.2 
 Mast cells are derived from CD34 progenitor cells in the bone marrow.3 Although most cells 
descending from progenitors in the bone marrow differentiate into mature cells before leaving the bone 
marrow, MCs leave as morphologically unidentifiable progenitors and differentiate into phenotypically 
identifiable MCs only after they infiltrate connective or mucosal tissue.4-6 In addition, fully granulated 
MCs in well-differentiated mast cell tumours (MCTs) can undergo mitosis, indicating that fully 
differentiated MCs have the potential to proliferate.7 
 In rodents, formalin-resistant connective tissue type MCs (CTMC), and formalin-sensitive 
mucosal type MCs (MMC) have been identified.8,9 Canine MC heterogeneity based on formalin 
sensitivity has been identified in the skin,10,11 trachea, lung, intestine and in MCTs.11,12 However, the 
classification used in rodents is not found to be appropriate for subtyping canine MCs.13,14 Instead, three 
subtypes exist in dogs based on their content of the proteases, chymase and tryptase, which are present in 
both normal and neoplastic MCs.11,15
 Mast cells can be recognized in tissues by their cytoplasmic granules when appropriately fixed 
and stained with cationic dyes that bind granule proteoglycans, resulting in metachromasia.16 These 
granules store mediators of inflammation, including histamine, proteases, chemotactic factors, cytokines 
and metabolites of arachidonic acid, conferring to MCs an important role in immunological, inflammatory 
and immediate-type allergic reactions.17-21 Extracellular release of MC granule contents can be 
precipitated by physical or chemical means, such as heat, trauma and toxins, or by immune mechanisms, 
such as antigen-specific IgE binding to IgE receptors on the MC cell surface.16,22-28 In addition, MCs are 
well known for their neoplastic transformation in solitary and multiple cutaneous MCTs, as well as 
visceral or systemic mastocytosis.29,30 The biological behavior of MCTs is highly variable and 
 
improvements in understanding of the natural history and prognostic indicators as well as the indications 
for multimodal therapy, will further result in better outcomes in canine patients with MCT. 
 
PATHOGENESIS OF MCTs 
The aetiology of MCTs is unknown but, as with most neoplasms is probably multi-factorial, and the well-
documented breed predispositions likely indicate an underlying genetic component. Recent work has 
implicated the stem cell factor receptor, KIT, in the aetiology of canine MCTs.31 KIT is a surface growth 
factor receptor, normally expressed on MCs and encoded by the proto-oncogene c-kit.32 KIT consists of 
an extracellular ligand-binding domain, a transmembrane region and a cytoplasmic tail with ligand-
dependent tyrosine kinase activity. Activated KIT binds and phosphorylates intracellular substrate 
proteins initiating a signalling cascade which culminates in a wide array of biologic activities including 
proliferation, migration, maturation, and survival of haematopoietic stem cells, MCs, melanocytes, and 
germ cell lineages.32-38 The ligand for KIT is stem cell factor, also known as steel factor, KIT ligand, or 
mast cell growth factor.39-42 KIT expression has been demonstrated immunohistochemically in both 
normal and neoplastic canine MCs, with higher expression in poorly differentiated MCTs.31,43-45 In 
addition, dissimilar cytoplasmic and cell membrane expression of KIT has been found between normal 
and neoplastic canine MCs, and aberrant cytoplasmic KIT expression due to c-kit mutations has been 
associated with poor clinical outcome.45-47 Several authors have reported a variety of c-kit mutations in 
canine MCTs, particularly in exon 11, including different point mutations and tandem duplications in the 
juxtamembrane coding region.35,44,45,48-54 However, mutations have not been described in other regions, in 
particular in the c-kit kinase domain which is the site of the most frequent mutation in human MCTs.55-57 
Moreover, internal tandem duplications reported in canine MCTs have not been reported in the c-kit gene 
of human beings. Various studies have shown that about 15% to 40% of all canine MCTs are affected by 
c-kit mutations.35,44,45,48-54 In addition, a significant association between mutations and tumour grade was 
demonstrated in two large studies in which 0/24 and 1/12 well-differentiated, 8/58 and 42/119 
intermediate grade, and 4/6 and 9/26 high grade tumours, respectively, were affected.48,51
 Mutations of c-kit, characterized by internal tandem duplications, produce a constitutively 
activated KIT protein in the absence of ligands35,49,58 that leads to extracellular signal-regulated kinase 
phosphorylation.58 Little is known about the consequences of these mutations. However, c-kit mutations 
and aberrant KIT protein localization are associated with increased expression of Ki67 and argyrophilic 
nucleolar organizing regions (AgNORs), both of which are markers of increased cellular proliferation.47 
Moreover, in vitro testing of drugs targeting the KIT tyrosine kinase receptor demonstrated inhibition of 
proliferation of canine MCT cell lines and primary neoplastic MCs, associated with cell-cycle arrest and 
apoptosis.59 Despite these findings, no genetic defects in c-kit are identified in more than 60% of canine 
MCTs. This suggests that, mutations in this gene are associated with the development or progression of 
some MCTs, but mutations in other genes are likely to be involved in the initiation and progression of 
most canine MCTs. 
 
 In addition to genetic mutations, some authors have suggested that chronic cutaneous 
inflammation may play a role in MCT development.60 However, only rare cases of MCTs associated with 
chronic dermatitis, scar formation or the application of skin irritants have been documented.61,62 Other 
studies have suggested a possible viral cause and MCTs have been transplanted to very young or 
immunocompromised laboratory dogs through tumour cells and cell extracts but unequivocal evidence of 
a viral aetiology is lacking.63-65 
 
HISTORY AND CLINICAL PRESENTATION  
The vast majority of canine MCT occur in the dermis and subcutaneous tissue. In addition, they are 
occasionally reported in extracutaneous sites, including the conjunctiva, salivary gland, nasopharynx, 
larynx, oral cavity, gastrointestinal tract, urethra and spine.66 Visceral MCTs (disseminated or systemic 
mastocytosis) are almost always preceded by an undifferentiated primary cutaneous tumour, and primary 
MC leukaemia is extremely rare.66,67 
 
Incidence 
Dogs have an unique risk of developing cutaneous MCTs68 which account for 7% to 21% of all canine 
skin tumours.69-76 Furthermore, MCTs are reported to be the most common canine skin tumour submitted 
for histology and diagnosed in veterinary teaching hospital populations68-70,72,77 with an incidence of 
129/100,000 dogs per year in one UK study of insured dogs.78 
 
Breed predisposition 
Breeds found to be predisposed to develop MCTs include boxers, Boston terriers, bull terriers, 
bullmastiffs, cocker spaniels, Staffordshire terriers, fox terriers, English bulldogs, dachshunds, labrador 
retrievers, golden retrievers, beagles, pugs, schnauzers, shar-peis, Rhodesian ridgebacks, Weimaraners, 
and Australian cattle dogs.68,70,72,79-82 In one study, boxers and Boston terriers represented more than 50% 
of dogs with MCTs and the relative risk of developing MCTs was found to be 16.7 for boxers and 8.0 for 
Boston terriers.69 The increased incidence in these two breeds may be related to their common bulldog 
ancestry. 80 Site predilection has also been reported for various breeds: hind limbs and multiple lesions in 
boxers and pugs, hind limbs in Boston terriers and American Staffordshire Terriers, the tail in Rhodesian 
ridgebacks, multiple lesions in Weimaraners and golden retrievers, and the head and hind limbs in 
English setters.79,83 
 
Gender 
Most studies report no gender predilection66,69,80-82,84 or association between gender and survival,81 with 
the exception of one European study in which female dogs were found to have a more favourable 
prognosis with chemotherapy than their male counterparts.85 It is, therefore, unclear whether sex 
hormones may have an impact on tumour behaviour.66 
 
 
Age 
The mean age of dogs at presentation is between 7.5 and 9 years,60,66,68,69,73,81,82,84,86-89 although MCTs are 
occasionally found in dogs as young as 4 to 6 months of age.73,90,91 
 
Tumour site and gross appearance 
Dogs with cutaneous MCTs are most frequently presented for the evaluation of a cutaneous mass, and 
only rarely for clinical signs related to the release of mediators from MC granules.67,68,74 Cutaneous MCTs 
are most common on the trunk (50% - 60%), followed by the extremities (25% - 40%), and the head and 
neck (10%).68-70,92,93 The scrotum, perineum, back and tail are less commonly affected.79 In general, a 
greater number of tumours affect the posterior part of the body (hind limbs, perineum and prepuce).67,71 
The gross appearance of MCTs varies widely and can mimic other cutaneous tumours and non-neoplastic 
conditions (Fig. 1). MCTs must, therefore, be considered in the differential diagnosis of any skin 
nodule.86 The gross appearance of MCTs correlates to some extent with histological grade.92 Low-grade, 
well-differentiated MCTs tend to present as a solitary, rubbery, slowly growing nodule with 1 to 4 cm in 
diameter, which are often present for over 6 months prior to diagnosis.66,72 These may be alopecic but are 
typically non-ulcerated. Another form of MCTs are subcutaneous tumours that may be soft and fleshy on 
palpation and are often grossly misdiagnosed as lipomas.66 Undifferentiated MCTs tend to grow rapidly, 
ulcerate, cause considerable irritation and may give rise to small satellite nodules in the surrounding 
tissues.66,72 Most MCTs are not pigmented, but occasionally erythematous and hyperpigmented nodules 
are found.68 The surrounding tissue may be inflamed and oedematous66 and can present urticarial swelling 
or diffuse areas of oedema and inflammation resembling cellulitis.86 Lesions on the distal extremities, lips 
and in the inguinal area may present as poorly defined areas of swelling or mimic acral lick 
dermatitis.29,61,94 In addition, diffuse MCTs can produce gross distension and deformation of the hind 
limbs in shar peis.95,96 
 Palpation of MCTs occasionally causes degranulation with release of histamine and other 
vasoactive substances that results in local vasodilatation, oedema and erythema, also known as Darier's 
sign.66,68,86 Likewise, manipulation of visceral MCTs can cause vomiting and abdominal pain.60 
 
Multiple MCTs 
In most dogs, MCT presents as a single cutaneous tumour but between 5% and 25% of dogs are affected 
with multiple skin tumours which may occur synchronously or sequentially.29,61,66,68,71,73,83,86,89,97,98 Breeds 
reported to be more frequently affected by multiple tumours include boxers, pugs, Weimaraners, golden 
retrievers and shar peis.79,83 A case of multiple pruritic MCTs that spontaneously regressed was also 
reported in a 3-week-old jack russel terrier.90 However, this may have been a hyperplastic MC 
proliferation29,66,68 or possibly a condition akin to urticaria pigmentosa in humans.86 
 
Paraneoplastic syndromes and complications of granule release 
 
Complications related to the release of the bioactive substances in MC granules (histamine, heparin, 
eosinophilic chemotactic factor and proteolytic enzymes) occur in up to one half of dogs with MCTs.74,97 
Delayed wound healing after surgical excision is a common problem attributed to proteolytic enzymes 
and vasoactive amines released by the tumour.66,67,87 Studies in mice suggest that released histamine binds 
to H1 and H2 receptors on macrophages causing the release of fibroblastic suppressor factor that decreases 
normal fibroplasia and delays wound healing.66 Furthermore, histamine and human mast cell leukaemia 
lysates have been shown to reduce keratinocyte proliferation and thus inhibit wound epithelialisation.66 
Local haemorrhage is frequently encountered during surgical excision, fine-needle aspiration and 
excessive manipulation of MCTs64 and is likely due to coagulation defects caused by released 
heparin.64,66,67,99,100 Indeed, prolonged coagulation time of blood taken from or around MCTs is frequently 
observed66 although prolongation of coagulation times from venous blood samples are observed in a small 
minority of patients.99 Since haemorrhage can be a serious complication of surgery, clinicians should 
anticipate local bleeding and try to avoid excessive tumour manipulation during biopsy or excision.66,64 
Fortunately, uncontrollable bleeding is rarely a problem during the surgical excision of MCTs.69 
Gastrointestinal ulceration due to MCTs can cause anorexia, vomiting, haematochezia, melaena, anaemia, 
abdominal pain and, in some cases, intestinal perforation and peritonitis.66,69,84,87 Such complications are 
usually restricted to aggressive high-grade or extensive MCTs.66,69,87 Nevertheless, gastrointestinal 
ulceration is found in about 35% to 83% of dogs with MCT at necropsy examination.101 The pathogenesis 
of gastrointestinal ulceration associated with MCTs appears to be caused by a combination of vascular 
damage, excessive gastric acid production through stimulation of H2 receptors on parietal cells and 
hypermotility.66,64,102 Malignant MCs contain 25 to 50 times more histamine than normal MCs103 and dogs 
with MCT have significantly higher plasma histamine and lower gastrin levels than normal dogs.102 The 
lower gastrin levels are thought to be the result of negative feedback from increased gastric acidity.102 
Plasma histamine and gastrin concentrations are not related to MCT stage, grade or tumour size, limiting 
their clinical usefulness in the diagnosis and prognosis of canine MCTs.66,104 Acute, potentially life–
threatening anaphylactic shock by sudden, massive release of histamine from neoplastic cells is very 
unusual, but episodes of collapse may be seen in dogs with extensive disease66,67,87 and can be an 
uncommon complication of tumour manipulation during surgery, especially if cryosurgery or 
hyperthermia are employed.67,103 
 
 
CLINICAL PROGNOSTIC FACTORS 
No single factor accurately predicts the biological behaviour or response to treatment in dogs affected by 
MCTs.97 Clinical factors that can influence the outcome include location,60,64,66,71 clinical appearance of 
the tumour,66,71,89,92,105 growth rate,66,89,92 size,89 presence of systemic paraneoplastic signs,60,66,72,74,89 
breed,68,70,72,79-83,88 sex,85 and clinical stage.66,85,92 However, the single most valuable factor is histological 
grade.64 
 
 
Tumour location 
Tumours in the nail bed, oral cavity, muzzle or inguinal, preputial, perineal and mucocutaneous areas are 
often correlated with a worse prognosis than those in other parts of the body,60,64,66,71,74,82,106,107 although 
this is not supported by all studies.93,108 In addition, survival of dogs  with incompletely resected MCTs 
that were treated with radiation therapy was greater for tumours located on the extremities than of those 
located on the trunk.109 
 
Tumour appearance  
Local tumour ulceration, erythema or pruritus have been associated with poorer prognosis.89,105 
 
Systemic signs 
Systemic signs, such as anorexia, vomiting, melaena, widespread erythema, oedema, and gastrointestinal 
ulceration are most frequently associated with visceral forms of MCT and are associated with a poorer 
prognosis.60,66,74,89,109 
 
Breed predilection 
Boxers are presented at significantly younger ages with MCTs than other breeds,82,88 and more commonly 
develop histologically low or intermediate grade MCTs with a more favourable prognosis.72,88 Although 
shar peis also develop MCTs at an early age (4 years old on average), these are frequently aggressive 
tumours.83,110 MCTs in labrador retrievers are also frequently more aggressive than in other breeds.83,110 
 
Growth rate and size 
The growth rate of MCTs (tumour volume divided by the duration of time the tumour has been present) is 
a significant prognostic factor.92 Indeed, MCTs that remain localised and are present for prolonged 
periods (months or years) without significant change are usually benign, and those present for over 7 
months carry a favourable prognosis.92 Furthermore, large tumours may be associated with a poorer 
prognosis.89 
 
Gender 
Only one study reported gender-associated differences in prognosis with female dogs doing better than 
males following treatment of MCTs with chemotherapy.85 
 
Clinical stage 
A clinical stage of 0 or I (Table 1) carries a better prognosis than any higher stage disease85,92,109 and 
metastasis at the time of initial diagnosis significantly shortens survival.93 However recent reports show 
that stage II MCTs can be treated successfully resulting in comparable disease free survival time to stage 
0 disease.111,112 In addition,  it has been shown that dogs with multiple MCTs treated surgically had a low 
metastatic rate and a good prognosis for a long term survival. 113 Postsurgical recurrence is thought to be 
 
associated with a poorer prognosis.60,105 These data suggest that with appropriate therapy, the clinical 
stage has minor prognostic value. 
 
Metastatic disease 
 MCTs are always considered potentially malignant,29,67 but the true metastatic potential of MCTs is 
unknown.66 Well-differentiated tumours have a metastatic rate of less than 10%, and intermediate 
tumours are considered low to moderate in metastatic potential.66,108 In addition to greater local 
infiltration, undifferentiated tumours have a much higher metastatic rate, ranging from 55% to 
96%.67,92,114 Differences in reported metastatic rates for different histological grades may be in part due to 
the somewhat subjective system of grading.66 
 Most MCTs first metastasize to local lymph nodes and then to the spleen (46%), liver (41%) or 
other visceral organs.29,66,73,74 Lung involvement is very uncommon.66 Neoplastic MCs may be observed 
in the bone marrow and in the peripheral blood in cases of widespread systemic dissemination.66 The 
visceral form of MCT (disseminated mastocytosis) is usually preceded by an undifferentiated primary 
cutaneous MCT.60,66,67 
 
DIAGNOSTIC WORKUP  
The diagnostic evaluation of dogs with suspected MCT has three goals: 1) definitive diagnosis by 
cytology and/or histopathology, 2) clinical staging, and 3) documentation of paraneoplastic clinical 
signs.68,115 
 
Tumour cytology 
Fine needle aspirates (FNAs) of dermal and subcutaneous masses is a simple technique and should be 
performed prior to surgery because a preoperative diagnosis of MCT influences the type and extent of 
surgical intervention.49,60,68,71 MCTs can generally be diagnosed by cytological examination of stained 
smears of FNAs.49,66,74,87,107 Indeed, FNA yields a correct diagnosis in 92% to 96% of histologically-
confirmed canine MCTs.66,82 Cytology of MCTs reveals a discrete round cell population with moderate 
amounts of cytoplasm containing purplish red cytoplasmic granules of variable number and 
size.60,68,71,72,103 The cells have a round to oval nucleus that may be masked by intense staining in highly 
granulated cells (Fig. 2). Other cells found on cytology are variable numbers of eosinophils and/or plump 
spindle cells, presumably fibroblasts. MC granules can be stained with routine haematological stains 
(Wright’s, Giemsa, Leishman, etc.) as well as rapid modified Romanowsky-type stains (Diff-Quik) used 
in most practices.116 However, granules in some MCTs stain poorly with rapid stains unless the slide is 
immersed for several minutes in the alcohol fixative.66,103,116 In addition, poorly granulated mast cells may 
be difficult to recognise (Fig. 3). 66,68,74 Although grading of MCTs requires histological evaluation, cell 
morphology and staining characteristics observed on cytological preparations give an indication about the 
degree of differentiation.68,103 Anaplastic or high-grade tumours normally yield a highly cellular sample 
with cells having a low number of cytoplasmatic granules, irregular nuclei and increased pleomorphism 
 
and mitotic figures.74,117 In some cases, poorly-granulated cells of anaplastic tumours may be more easily 
recognized in cytological smears and imprints than in histological sections due to the greater resolution of 
granules in cytology.103  
 
Further diagnostic workup 
The extent of ancillary diagnostic workup and staging following a cytological diagnosis of MCT has 
recently be re-evaluated and depends on the presence or absence of negative prognostic factors60,66 as 
illustrated by Thamm and Vail (Fig. 4).66 The minimum workup in cases requiring presurgical staging 
consists in FNA of the draining lymph nodes even if they are normal in size107 and abdominal 
ultrasound.60,66 Evaluation of the sublumbar lymph nodes may require ultrasonography or other imaging 
techniques.67 If enlargement of the sublumbar nodes is present, metastatic disease should be presumed.67 
The interpretation of lymph node cytology is not always easy because MCs can be found in lymph node 
aspirates in normal animals.68,87 The WHO guidelines suggesting that cytological specimens need only be 
evaluated for the presence or absence of MCs may, therefore, lead to an incorrect diagnosis of 
metastasis.118 Current recommendations are that metastasis to a lymph node should be diagnosed by 
cytology if MCs represent more than 3% of the cell population in the aspirate.87 However, even with this 
criterion, up to 25% of normal dogs would be diagnosed with a metastatic MCT and evaluation of the 
degree of cytological differentiation and clustering or aggregation of cells, should also be considered in 
the final cytological diagnosis of metastatic disease.66,68,87 In suspicious cases, surgical extirpation of a 
lymph node and histological assessment should be considered.66 
 Knowledge of the extent of gross MCT margins allows more appropriate planning for surgery or 
radiotherapy and the exact extent of local tumour margins was upgraded in 19% of cases with ultrasound 
and in 65% of cases with computed tomography in one study.119 However, it has to be considered that 
such examinations add additional costs and, therefore, may only be justified if the tumour location does 
not allow wide excisional margins. 66,118 
 Thoracic radiographs are seldom indicated as MCTs very rarely metastasize to the lungs. 
Moreover, when lung metastasis does occur, diffuse interstitial infiltrates are more common than discrete 
nodules.66,103 Nevertheless,  thoracic radiographs are reasonable in older patients to rule out an unrelated 
disease that may complicate anaesthesia if an expensive or invasive procedure is necessary.66 
 Aspiration cytology of sonographically suspicious lesions in the liver or spleen is recommended 
but interpretation can be complicated by the presence of non-malignant MCs in these organs in normal 
dogs.66 
 The validity of screening buffy coat smears in dogs with cutaneous MCTs for possible systemic 
involvement has been disputed because mastocytaemia is more frequently observed in dogs with 
inflammatory conditions than MCT.66,120 Moreover, the visceral form of MCT constitutes a small 
minority of all canine cases and many authors have abandoned the routine examination of buffy coat 
smears, reserving this diagnostic procedure for selected cases.60,66,87,97 
 
 Equally, bone marrow aspiration is no longer recommended in the routine staging of canine 
MCT.66 The vast majority of dogs with cutaneous MCTs do not have circulating MCs or evidence of bone 
marrow infiltration66,87 and involvement of peripheral blood or bone marrow is unlikely in the absence of 
disease in the regional lymph nodes or abdominal organs.66,87 Moreover, visceral MCT carries a very 
grave prognosis and the additional presence or absence of neoplastic MCs in blood or bone marrow rarely 
alters treatment decisions. 
 
Clinical staging 
The WHO clinical staging system for MCTs71 (Table 1) is widely used together with the histological 
grade in the aid of prognosis, therapy selection and in clinical trials.60,66-68,86,87 However, recent studies 
have questioned the utility of this system, especially with respect to clinical stage III tumours.83,105,121 In 
general, clinical stage 0 and I tumours have a better prognosis than higher stage disease.85,92 According to 
the WHO staging system multiple cutaneous nodules and large infiltrating tumours are staged identically 
as stage III although several studies suggest that no difference in outcome exists between patients with 
single MCTs and those with multiple MCTs of the same histological grade.83,89,122 Many authors, 
therefore, suggest that the category of ‘multiple tumours’ should be removed from the stage III grouping, 
and each tumour should be staged individually in dogs with multiple tumours.66,68,87 Second, the  term 
‘infiltrating’ is  misleading since according to the histological grading system for MCTs of Patnaik81 all 
grade II and III tumours infiltrate the subcutis and, therefore, would become clinical stage III although the 
prognosis of some grade II tumours is fairly good.87 A preliminary study suggests that some subcutaneous 
MCTs even have a slightly better long-term prognosis than higher grade dermal variants.123 As a 
consequence of the above mentioned weaknesses, a significant number of dogs are probably treated more 
aggressively than necessary. 87 Therefore, it is necessary to update the WHO clinical staging system for 
cutaneous MCTs but so far, no consensus exists over the best staging procedure for canine MCTs and 
various authors use their own systems.68,97 
 
Histological findings and staining properties 
Although FNA cytology is convenient for diagnosis, it does not provide a histological grade and 
excisional samples should be submitted for histological grading and margin assessment.29,66,68,87,97 The 
diagnosis of MCTs is straightforward in most cases. They present as nonencapsulated dermal and/or 
subcutaneous infiltrative growing masses composed of round cells arranged in densely packed cords or 
loose sheets. Cellular morphology depends on the degree of differentiation but most neoplastic MCs have 
a distinct cell membrane, a central round nucleus and variable numbers of cytoplasmic granules that stain 
light-grey blue with haematoxylin and eosin or purple with metachromatic stains such as toluidine blue. 
The collagenous stroma varies from scant to abundant, and may appear oedematous or hyalinised. 
Variable numbers of eosinophils are either dispersed throughout the neoplastic mass or form aggregates. 
Marked deposition of mucin and perivascular hyalinization may be seen in response to the eosinophilic 
 
infiltration, and eosinophilic vasculitis may be present. Foci of marked eosinophilic degranulation may 
entrap brightly eosinophilic collagen bundles to form flame figures. 
 Well differentiated MCTs (Fig. 5) consist of fairly well circumscribed but nonencapsulated 
masses composed of round cells with a central small nucleus, a single inconspicuous nucleolus and 
abundant, highly granulated cytoplasm. Cytoplasmic borders are distinct, cellular variation is rare and 
mitotic figures are almost never seen. Tumour cells are arranged in rows or loose sheets separated by 
collagen bundles. The overlying epidermis is usually intact. These tumours are confined to the 
interfollicular dermis in the Patnaik grading system (Table 2), however, in the authors` experience and of 
others, tumours with the above described morphology may also invade the subcutaneous tissue.29,124 
 Intermediate-grade MCTs (Fig. 6) are not as well circumscribed and are comprised of closely 
packed cells with distinct cell borders, an increased nuclear-to cytoplasmic ratio and fewer granules than 
a well-differentiated tumour. Giant, binucleate or occasional spindle-shaped cells may be present. Small 
numbers of mitotic figures are seen. The tumour cells are arranged in groups separated by a collagenous 
stroma that may be thick or hyalinised with areas of oedema and necrosis. 
 Undifferentiated (anaplastic) MCTs (Fig. 7) are poorly circumscribed and the majority of them 
consist of poorly granulated round to polygonal highly pleomorphic cells. The nucleus is large, vesicular, 
and irregular in shape and has several nucleoli. Bi- or multinucleated cells are present and mitotic figures 
are numerous. The tumour cells infiltrate the subcutis and deeper tissues. Necrosis and ulceration are 
common secondary features.29,30,125  
 Cellular density and morphology varies significantly between grades, and poorly differentiated 
MCTs can be confused with other round cell tumours. Thus, numerous attempts have been undertaken to 
apply histochemical and immunohistochemical stains for a definitive diagnosis of poorly differentiated 
MCTs. In one study that examined the use of the histochemical stains, alcian blue pH 2.5, azure and 
eosin, Giemsa, Luna’s method for MCs, periodic acid-Schiff reaction, safranin O, toluidine blue, Torren’s 
method, Unna’s method, chloracetate esterase, and the affinity stains, avidin peroxidase, wheat germ 
agglutinin, and concavalin-A agglutinin, as well as immunohistochemical stains with CD68, none of the 
staining techniques was found to be ideal.126 Based on a previous publication and our own experience, 
immunohistochemistry with antitrypase antibodies or histochemical stains for chymase activity may, 
however, be helpful in the diagnosis of poorly granulated MCTs.127 Indeed, 7/7 (100%) grade I, 6/7 
(85.7%) grade II, and 3/7 (42.9%) grade III tumours were diagnosed as MCTs based on these stains.127 In 
addition, MCTs are positive for the common leukocyte marker, CD45, and retain variable expression of 
the leukocyte antigens, CD45RA and CD18.29 As discussed earlier, MCTs also express KIT, but none of 
these antigens is specific for MCTs. Very recently, the production and characterization of mouse 
monoclonal antibodies specific for canine MCTs, were reported.37 In this study, one of the antibodies 
(MAb 9-3; IgM) recognized a 74 kDa protein on the surface and the cytoplasmic granules on all eight 
MCTs investigated but not on normal tissue MCs. A second antibody (MAb 80; IgM) recognized a 167 
kDa and a 248 kDa protein on both neoplastic and normal tissue MCs. Further studies with larger 
numbers of tumours will show if MAb 9-3 proves to be a suitable marker for the diagnosis of poorly 
 
differentiated canine MCTs. For the present, however, a final diagnosis of undifferentiated MCTs remains 
difficult and may require the use of multiple antibodies to exclude other poorly differentiated round cell 
tumours. 
 
Grading based on morphology 
Three histopathologic classifications have been proposed to identify the degree of differentiation of 
canine MCTs.61,81,92 All grading systems differentiate between well-differentiated (low grade, mature), 
intermediate-grade, and undifferentiated (poorly differentiated, anaplastic, high grade) MCTs. Among 
them, the classification proposed by Patnaik et al.81 (Table 2) is considered to be the most complete and is 
the most frequently used system.46,47,51,128-138 Whereas Hottendorf and Nielsen did not assign any numbers 
to the grade of differentiation, well differentiated tumours are considered as grade I by the Patnaik system 
but grade III by the system proposed by Bostock.61,81,92 To avoid confusion, the terms well differentiated, 
intermediate, and poorly differentiated are frequently employed instead of grade numbers, especially if 
the grading system used is not explicitly reported. Numerous studies have shown significant differences 
between well- and poorly-differentiated MCTs in survival times.81,92,126,128-130 However, histological 
grading is of limited prognostic value for tumours of intermediate differentiation (more than 40% of all 
canine MCTs) as these tumours behave unpredictably in a benign manner, recur or metastasise.118,131 In 
addition, studies have shown variation between pathologists using identical grading systems in their 
assignment of histological grades for MCTs.132,133 This is mainly due to the fact that histological grading 
is based on the use of subjective parameters such as invasiveness, cellularity, cellular morphology, and 
mitotic index.132-135 As a result, various attempts have been undertaken to use more objective methods to 
assess the grade of MCTs. 
Nuclear morphometry has been shown to be significantly associated with histological grading of 
various tumours in humans and animals.136-141 Two groups investigated nuclear morphological features as 
possible indicators of histological grade in canine MCTs.135,142 These groups demonstrated  significant 
differences between grades I and III and grades II and III for mean nuclear area, nuclear diameter and 
nuclear perimeter but differences between grades I and II were not significant (Table 3). The mitotic 
index (MI) has been shown to be a strong predictor of outcome for a variety of human and canine 
cancers143,144 and several studies have demonstrated a prognostic value of MI in canine MCTs (Table 
3).124,134,135,142,145-147 Moreover, in one recent study, the median survival for dogs with a MI ≤ 5 was 
significantly longer (70 months) than for those with a MI >5 (2 months), regardless of histological 
grade.147 However, in the authors’ experience, MI may be difficult to assess in highly granulated MCTs. 
The results of the studies undertaken to give a prognostic indicator with different morphological features 
and morphometric variables are summarized in Table 3. In conclusion, morphological features are useful 
in predicting MCT behaviour but predicting prognosis in intermediate-grade MCTs still remains 
problematic. The MI seems to be a strong predictor for the prognosis with regard to survival time. 
However, in the two studies in which the impact of MI on the rate of recurrence was investigated, the 
results are controversial.134,146 Nevertheless, the MI is an objective measure and may help to limit inter-
 
observer variation in the histological evaluation of MCTs. A problem that remains to this date is that the 
various studies used different cut-off values and thus the data are still difficult to apply in a diagnostic 
setting.  
 
Grading based on proliferation markers 
Uncontrolled cellular proliferation is a hallmark of cancer and, as such, measures of cellular proliferation 
have been extensively used in an attempt to predict behaviour in neoplastic disease.47,124,126,131,133,138,143,152-
158 In veterinary medicine, the most commonly used methods include staining for argyrophilic nucleolar 
organizer regions (AgNORs), immunohistochemistry proliferating cell nuclear antigen (PCNA) and for 
Ki67, all of which have been investigated in canine MCTs (Table 3).148,149 
 AgNORs are areas in the nucleus that are associated with proteins, such as nucleolin and 
nucleoplasmin substructures, involved in ribosomal RNA transcription.150 They are widely used as a 
marker of tumour kinetics and tumour metabolic activity. AgNORs bind silver molecules and can be 
visualised by light microscopy using a silver-based histochemical stain.151 The quantity of AgNORs per 
nucleus has been shown to be proportional to the rate of cell proliferation or cell doubling time in vitro152-
154 and the rate of tumour growth in vivo.155-157 A number of studies have shown that higher AgNOR 
counts in MCTs are associated with increased mortality, local recurrence and metastasis.47,124,134,158 
PCNA is a protein that interacts with DNA polymerases, acting as an auxiliary factor for DNA 
replication and repair.159,160,161 Although PCNA has an extended half-life and is involved  in multiple 
nuclear functions, maximal PCNA expression is commonly seen in the synthesis phase of  the cell cycle 
(S-phase).49,162,163 Two studies have shown an association between PCNA expression and increased 
mortality in canine MCTs.47,134 However, only one of these two studies found an association between high 
PCNA expression and recurring or metastatic tumours47,134 and other studies found no correlation between 
PCNA expression and prognosis.128,158 Furthermore, PCNA expression has not been found to be a 
prognostic marker independent of the histological grade in any study.47,126,128,134,158 
 Ki67 is a nuclear protein that is expressed in all active phases of the cell cycle but is not present 
in noncycling cells.164,165 The relative number of Ki67-positive cells is used to determine the proliferation 
index or the relative number of cells actively involved in the cell cycle (growth fraction).148,149,164,165 A 
high Ki67 expression in MCTs has been shown to be associated with increased mortality, the rate of local 
recurrence and metastasis.47,128,158 In addition, Ki67 was found to be better than AgNORs for identifying 
MCTs associated with decreased survival, although AgNORs were better markers for identifying MCTs 
with a decreased disease-free interval.47 Importantly, Ki67 has been shown to be a prognostic factor that 
is independent of histological grade.47,158 Thus, Ki67 immunohistochemistry can be used as an objective 
prognostic marker in MCTs. 
 KIT expression was found to be significantly correlated to histological grade, Ki67 expression, 
AgNORs and tumoural necrosis in one study.166 Furthermore, significant correlations were also 
established between Ki67 and AgNORs with histological grade, tumour necrosis and epidermal 
ulceration. In this study, no differences were observed between focal and diffuse cytoplasmic KIT 
 
staining and histological variables.166 The latter finding is in contrast to results presented in other studies, 
which demonstrated an association between aberrant cytoplasmic KIT expression and either increased 
proliferation index, the presence of c-kit mutations, increased local recurrence or decreased survival.45-47,51 
 Tumour angiogenesis plays a key role in tumour growth and metastasis167,168 and the prognostic 
role of intratumoural microvessel density (IMVD) has been demonstrated for canine mammary tumours 
and squamous cell carcinoma.169-172 IMVD has also been evaluated by immunohistochemical staining of 
canine MCTs for the endothelial marker factor VIII (von Willebrand’s factor)-related antigen, and found 
to be associated with tumour recurrence and mortality.145 
Abnormal DNA content (aneuploidy) was investigated in 40 canine MCTs using flow 
cytometry.173 In this study, over 70% of the MCTs were diploid. When comparing diploid and aneuploid 
tumours, a significant difference was found between clinical stage I versus non-stage I tumours but only a 
trend towards shorter survival was found in dogs with aneuploid tumours.173 
Mutation of the p53 gene is the most common genetic alteration known to occur in human 
cancer.174 The product of the p53 tumour-suppressor gene is a nuclear transcription factor whose 
functions include cell cycle arrest in cells with damaged DNA, induction of transcription of DNA repair 
enzymes, and the induction of apoptosis in cells that have sustained irreparable genetic damage.174-177 Two 
studies investigated p53 immunoreactivity in canine MCTs but neither could show an association with 
survival or tumour recurrence.129,178 
Similarly, expression of survivin, an inhibitor of apoptosis, was investigated in canine MCTs but 
no association was found between survivin expression and survival.158 
Matrix metalloproteinases have been associated with tumour invasion and metastasis in a variety 
of neoplasms in humans and animals.179-181 Matrix metalloproteinases 2 and 9 are secreted by canine 
MCTs and activated by exocytosed chymase.68, 204 Their expression in MCs is regulated by KIT ligand 
and tumour growth factor-β.182,183 Moreover, undifferentiated MCTs were found to express higher levels 
of these enzymes than intermediate-grade MCTs.184 
 Vascular endothelial growth factor (VEGF) has also been investigated as a mediator of disease-
related angiogenesis and potential autocrine growth regulator of neoplastic cells.185-188 Although canine 
MCTs were found to express both VEGF and VEGF receptors,VEGF was not found to be a growth 
regulator in canine MCTs.189 
The results of all the studies investigating proliferation markers as prognostic factors are 
summarized in Table 3.  From these studies it can be concluded that Ki67 and AgNORs seem to be the 
most valuable factors predicting MCT behaviour. Of these, the Ki67 index is much easier to assess and is 
a factor predictive of prognosis independent of Patnaik grading. However, the various studies 
investigating Ki67 have used different cut-off values to differentiate between tumours that are likely to 
have a favourable prognosis and those that are likely to have a poor prognosis, making practical 
widespread application of a Ki67 index difficult. Thus, the MI which can be assessed much easier in a 
diagnostic setting seems to be equally valuable. 
  
 
TREATMENT OF CANINE CUTANEOUS MAST CELL TUMOURS  
Treatment decisions are based on the clinical presentation of the disease and on the presence or absence 
of prognostic factors. There are numerous publications that  evaluate various treatments and combinations 
of those. Unfortunately, many of these reported studies were done in a retrospective way, based on small 
number of cases, lacked appropriate concurrent control groups and have included MCT’s of various 
clinical grades and stages necessitating careful interpretation of the findings. The following section is a 
more practical approach to treatment options and appropriate management of this disease.  
 
Well-differentiated to intermediate grade MCTs 
The management of well-differentiated (grade I, low grade) and intermediate grade MCTs for most 
anatomic sites consists in complete surgical resection. Various reports describe effective local tumour 
control in about 84% to 89% of grade II MCTs after complete surgical removal with local failure reported 
in 5% to 11% of the cases and distant metastasis in 5% to 22%. However, many studies report the 
development of new MCTs in up to 44% of the cases.89,93,190-193 
The historically suggested 3cm surgical margins194 for resection of canine MCTs have recently 
been replaced by studies demonstrating that a 2cm lateral margin and a deep margin of one fascial plane 
is sufficient for the complete excision of most grade I and II MCTs.191,195 For cases with clean excision of 
stage I well-differentiated to intermediate grade tumours a rigorous re-evaluation schedule and close 
monitoring for recurrence rather than adjuvant therapy is recommended (Fig. 6).66 Presurgical 
consolidation and reduction of tumour burden with prednisone can be realized in 70% and will improve 
the likelihood of obtaining complete resection margins.121,196  
In a recent report of incompletely excised grade II MCTs, 23% of all tumours recurred.193 
Adjuvant therapy with radiation is known to improve local tumour control and the incorporation of 
further prognostic factors, such as Ki67 scores or MI may help to select patients that are most likely to 
profit from ancillary local therapy.147,193 Tumours on the extremities, for example, can almost always be 
controlled with amputations, but the routine use of adjuvant radiotherapy and marginal surgical excision 
yields high local control rates as well as excellent functional outcome. Incompletely excised intermediate 
grade MCTs in all locations, treated with adjuvant radiation therapy result in a 1- to 2-year disease free 
interval (DFI) in 81% to 95% of cases.106,109,192,197,198 In contrast to “high-risk” tumours (e.g. tumours 
occurring at mucocutaneous junctions, grade II stage II or grade III MCTs),112,199-201 prophylactic 
irradiation of cytological negative lymph nodes has not been found to increase overall survival.192 
 
Well-differentiated to intermediate grade MCTs with lymph node involvement 
For dogs with well-differentiated to intermediate grade, solitary cutaneous tumours and metastasis to 
regional lymph node (stage II), several approaches have been described. Good outcomes with a median 
DFI of 40.6 months have been found for combined therapy with surgery and irradiation.190 While 
adjuvant chemotherapy is also possible, the need for systemic therapy in these cases is questionable. 
 
 
High grade or high-risk MCTs 
The median survival for patients with high-risk tumours (e.g. mucocutaneous, gingival, perineal, 
prepucial, nail bed), grade II stage II or grade III MCTs varies between 3.5 and 20 months after surgical 
excision alone and combination of surgery and radiation therapy, respectively.81,134,202,203 In spite of 
acceptable results with surgery and radiotherapy,202 the majority of veterinary oncologists feel that local 
therapy alone is insufficient for optimal control of high-grade MCTs.112,199-201 The outcome of such cases 
treated with a multimodal approach aiming at adequate local control and additional use of prednisone / 
vinblastine chemotherapy yielded superior results with a DFI of 45 months and 65% of patients alive at 3 
years (Fig. 8).112,199-201 When wide surgical excision is not possible, cytoreductive surgery or palliative 
radiation using coarse fractions of 6-8 Gy with total doses of 24-36 Gy, followed by systemic 
chemotherapy with prednisone / vinblastine may be considered. 66 As adequate local control is practically 
impossible in these cases, prognosis is only fair with median survival of approximately 5 months.105 
 
Metastatic or recurrent MCTs 
A large number of patients not cured of their disease during initial treatment will develop local and/or 
loco-regional failure (5% to 23%) in the absence of distant metastatic disease.118,131,193 In such cases, re-
evaluation with staging is necessary and treatment should follow similar rules as for primary disease. 
Systemic treatment with vinblastine /  prednisone in one study involving mostly incompletely or 
marginally resected intermediate grade MCTs yielded low rates of local recurrence (3.7%) and metastatic 
disease (15%).204 In addition, up to 44% of dogs cured of a previous MCT, will develop de novo MCTs 
which require individual staging and grading.89,190-193 
 In cases of visceral metastatic disease, any attempt of local control should be accompanied by 
systemic therapy consisting in cytotoxic chemotherapy and ancillary therapy aiming at controlling or 
reducing the systemic effects of release of MCT granules. The recommended choice of chemotherapy is 
vinblastine / prednisone,105 or the combination protocol using vinblastine / cyclophoshpamide / 
prednisone.205 CCNU (lomustine) has also been shown to result in measurable, albeit short lived response 
(2.6-5 months) in 42% to 47% of macroscopic MCT.206 Many oncologists are using a protocol that 
incorporates vinblastine / CCNU / prednisone (Table 4), however, results on the outcome of this protocol 
in peer reviewed literature is still pending. 
 
External beam radiation therapy 
The use of external beam radiation therapy is recommended for postoperative residuals, microscopic or 
subclinical disease, if further resection is not possible. Furthermore, radiation therapy can also be applied 
pre-operatively in order to reduce tumor size prior to surgery.207  Radiation therapy at low doses of 40-45 
Gy or hypofractionated protocols yield a 1-year tumour control rate of about 44% to 78% for macroscopic 
tumours.109,121,208 Control rates and duration may be improved with the application of higher total doses of 
up to 57 Gy, but the use of radiation as a single modality for MCT should be reserved for nonresectable 
locations.207 Combined treatment of radiation therapy and surgery greatly improves tumour control, 
 
especially in cases where surgery alone is incapable of controlling the disease due to functional or 
cosmetic constraints.207 DFIs of 94% at 1 year and 80% at 5 years have been reported following about 54 
Gy radiation of intermediate grade, stage 0 disease.197,198 As previously mentioned, prophylactic 
irradiation of the regional lymph node underlies debate, but some institutions routinely treat negative 
lymph nodes with 48 Gy (16 fractions) and positive nodes with 54 Gy (19 fractions).190,198 For loco-
regional disease with systemic spread, palliative radiation can be considered as an (additional) option for 
local palliation of disease. 
 Generally, a minimum of a 3cm margin of normal appearing skin is included in the radiation 
field. For lymph nodes, the prescribed radiation fields are generally succinct to include the node and 
about 1cm margins. For definitive therapy, total doses of 48-57 Gy are described in 15-19 fractions.207 
 
Chemotherapy 
The use of chemotherapy in the management of canine cutaneous MCTs primarily aims at the treatment 
of disseminated, non-resectable or high-grade tumours and may be considered for microscopic disease, if 
radiation therapy – the primary choice for microscopic residual disease - is not feasible. Various 
chemotherapeutic drugs and protocols have been evaluated in macroscopic canine MCT201,205,209-213 and 
several studies have used chemotherapy as adjuvant after surgical removal and / or irradiation of the 
tumour.112,199-201,205,209 The response of cutaneous MCTs to prednisone as a single agent,214 prior to 
surgical excision or irradiation (neoadjuvant),121,196 and in combination with chemotherapeutic agents 
such as vinblastine112,199-201, vinblastine / cyclophosphamide205,209 or cyclophosphamide / vincristine / 
hydroxyurea210 was described in several reports.  
The response rate to single agent chemotherapy for measurable disease was reported in four peer-
reviewed publications and ranges from 7% to 13% for the vinca alkaloids (vincristine: 7%, vinblastine: 
11.8% and vinorelbine: 13%) to 44% for the alkylating agent CCNU.211-213,215 Only the duration of 
response to CCNU monotherapy was described and found to be short-lived with 2.6 months duration.213 
While the overall objective response to single agent systemic prednisone therapy has been observed to be 
20% to 70%, there was a lack of durable efficacy in the only controlled clinical trial.214 In the other two 
studies describing the response of cutaneous MCTs to oral prednisone treatment, response was evaluated 
when the drug was used as neoadjuvant in order to facilitate combined treatment such as surgery or 
radiation therapy.121,196 However, the inclusion of prednisone into chemotherapeutical protocols has 
produced overall response rates of 47% to 64%201,205,210 and the 47% overall response found for the 
combined therapy of vinblastine and prednisone and the 44% response rate to CCNU monotherapy has 
todate directed these protocols as standard of care in the management of this disease. While a pilot study 
using a cyclophosphamide / vinblastine / prednisone combination demonstrated a 78% response rate in 
dogs with measurable metastatic MCT,209 the efficacy of this protocol combining vinca alkaloid with an 
alkylating agent and prednisone has been recently confirmed with a measurable 64%response of 
comparable duration to previously described combined protocols.205   
 
For combined therapy aiming at adequate local control of the primary and regional metastatic 
tumour with surgery and/or radiation therapy, the several chemotherapy protocols have shown to increase 
the DFI up to 43.5 months (Table 4).112,199,201,205 Trials including CCNU as part of combined 
chemotherapeutical protocols for cases with or without adequate local control of the primary tumour are 
underway with results presented at scientific meetings, but confirmed peer-reviewed results are still 
pending.  
The prevalence of toxicity was described to be up to 26% for combined therapy of vinblastine / 
prednisone, with 5% to 6.5% of moderate to severe toxicities including vomiting and / or neutropenia 
with fever necessitating hospitalisation or discontinuation of treatment.112,199,201 In the study using 
vinblastine / cyclophosphamide / prednisolone, the toxicities were described to be mild with 11.4% to 
14.2% mild myelosuppressive and 2.8% moderate gastrointestinal toxicity.205 The acute dose-limiting 
neutropenia after administration of CCNU was found to be moderate to severe in up to 41%.213 CCNU 
has also been associated with cumulative, dose related chronic hepatotoxicity and other toxicities such as 
fever, ascites, pleural effusion.213,216  
 
Medical treatment of systemic signs 
For clinically symptomatic problems related to excessive histamine release, a combination of H1 and H2 
blocker therapy is recommended. Recommendations include the use of these agents for systemic or local 
signs (Darier’s sign), cytoreductive surgery (where the tumour is likely to be manipulated) and where 
degranulation is expected to occur in situ (treatment of macroscopic disease with radiation or 
chemotherapy) (Table 5).66,121  
 
Other treatment modalities 
Other local therapies, including intralesional brachytherapy,217 photodynamic therapy218and the use of 
intralesional corticosteroids or deionized water178,219-221 have been described, but thorough investigation of 
these treatments in large patient populations is lacking. In addition, these treatment modalities negate the 
possibility to assess local tumour control by histological evaluation of margins. 
 Several drugs targeting the KIT tyrosine kinase receptor are being tested in vitro59 and some 
clinical response in dogs with MCTs has already been noted in a phase I study of a tyrosine kinase 
inhibitor.222 
 The use of biological response modifiers (i.e. agents that modify the relationship between the 
tumour and host) have been studied for years in veterinary medicine. The approach for treatment of 
cutaneous canine MCT was made by using the immunomodulatory and antitumour effect of LDI-100, a 
preparation containing human chorionic gonadotropin (HCG) and bacillus Calmette-Guerin (BCG). The 
28.6% clinical responses were comparable to single-agent vinblastine chemotherapy, however, with 
significantly less side effects.222 
 
CONCLUSIONS 
 
Dogs have a unique risk to develop cutaneous MCTs, which account for up to 21% of all skin tumours. 
The aetiology of MCTs is probably multi-factorial and, to some degree, influenced by genetic 
components. Mutations in the proto-oncogene c-kit are present in up to 40% of all dogs with MCTs, 
indicating a role of stem cell factor receptor in the aetiology of some canine MCTs. 
 The diagnostic workup of dogs with suspected MCT includes a definitive presurgical diagnosis 
with cytology and/or histopathology, clinical staging, the screening for metastasis, as well as 
documentation of clinical paraneoplastic signs. The diagnosis of MCTs by FNA cytology or 
histopathology is straightforward in the majority of cases. Accurate prognosis is, however, more 
challenging. Histological grading is based on the use of subjective parameters and has proven of limited 
value for predicting biological behaviour of intermediate grade MCTs. Investigation of objective 
parameters likely to be useful for prognostication, including mitotic index, various proliferation markers, 
KIT- and p53 expression, KIT and tryptase staining pattern as well as IMVD have been investigated. 
Amongst these, MI, Ki67 and AgNOR expression currently appear to be the most useful parameters, 
although the studies have used different cut-off values and thus, results are not yet easy to use in a 
diagnostic setting. 
 The optimal management of MCT is still a challenge for oncologists because of their diverse 
presentation and behaviour. Improved understanding of the natural history and prognostic indicators of 
MCT, as well as the role and indications for multimodality therapy has resulted in increasingly better 
outcomes. 
Local disease control remains the overriding concern, as inadequate initial local treatment often 
leads to recurrences. The timing and integration of various treatment modalities are often specific to the 
clinical situation, and this coordination is best achieved by preoperative multidisciplinary evaluation of 
the patient. 
 
 
 
Figure and Table Legends (Figures available on request) 
 
Figure 1: Six year old Staffordshire Bullterrier with a mast cell tumour on the ear margin. An alopecic 
firm and exophytic nodule of 8 mm in diameter is visible. 
 
Figure 2: Fine-needle aspirate smear of a mast cell tumour showing mainly highly granular mast cells: 
staining is so intense that cellular morphology is often obscured (May-Grünwald Giemsa). 
 
Figures 3: Aspirate smear from a mast cell tumour showing a highly cellular preparation of poorly 
granular mast cells with several nucleoli, moderate to marked variation in cell and nuclear size, and many 
mitotic figures (May-Grünwald Giemsa). 
 
Figure 4: Suggested diagnostic steps for canine cutaneous mast cell tumours 
 
Figure 5: Well differentiated mast cell tumour. Note that tumour cells are loosely arranged and separated 
by collagen bundles. Cells have a well granulated cytoplasm and distinct cell borders. There is little 
cellular pleomorphy. Haematoxylin and eosin, x400 
 
Figure 6: Intermediate differentiated mast cell tumour. Note the closely packed cells which have a finely 
granulated cytoplasm and distinct cell borders. Nuclear pleomorphy is moderate and mitotic figures are 
rare. Haematoxylin and eosin, x400 
 
Figure 7: Poorly differentiated mast cell tumour. Note the pleomorphic non granulated cells, the variably 
sized and shaped nuclei with a prominent nucleolus and the high number atypical mitotic figures. 
Intermingeled with the tumour cells are numerous eosinophilic granulocytes. Haematoxylin and eosin, 
x400 
 
Figure 8: Six year old Tervueren with an ulcerated mast cell tumour on the lateral nose after four weekly 
cycles of therapy with vinblastine/prednisolone. The tumour size was reduced by more than 50% prior to 
surgery, which was then possible to be performed with clean margins. 
 
Table 1: World Health Organization Clinical Staging System for Mast Cell Tumours 
 
Table 2: Histological grading of mast cell tumours suggested by Patnaik et al. 198481
 
Table 3.  Summary of significant results available with regard to prognostic indicators for canine 
cutaneous mast cell tumour outcome 
 
 
Table 4: Selected chemotherapy protocols for treatment of canine cutaneous mast cell tumour to be used 
in combination therapy aiming at adequate local control of primary and local metastatic disease 
 
Table 5: Medical treatment of systemic symptoms related to mast cell degranulation 
 
Table 1: 
  
Protocols Dose Frequency of administration 
VBL: 2 mg/m2 i.v. Once weekly for 4 weeks,  
followed by 4 treatments every 2 weeks 
Prednisone / 
Vinblastine (VBL) 
Prednisone:  
2 mg/kg p.o.  
1 mg/kg p.o. 
1 mg/kg p.o. 
 
Week 1: sid 
Week 2 +3: sid 
Thereafter: every other day 
   
CCNU (lomustine) 60-90 mg/m2 p.o. Once every 3 weeks, four times 
   
Adapted from [Rassnik et. al. 1999; Thamm et. al. 1999 and 2006] 
 
 
 
Table 2:  
 
In case of… Drug group Example Dose 
H1 blocker Diphenhydramine 2-4 mg/kg p.o. bid 
Rantitidine 2 mg/kg p.o. bid H2 blocker 
Cimetidine 4 mg/kg p.o. tid 
Suspected release of vasoactive 
substances by degranulating MCT 
Proton pump 
inhibitor 
Omeprazole 0.5-1 mg/kg p.o. sid 
Evidence of gastric or duodenal 
ulceration 
Sucralfate  0.5-1 g p.o. tid 
    
Adapted from [Thamm and Vail 2007] 
 
 
 
Table 3.   
 
Prognostic indicator Outcome Total 
no. 
 of 
cases 
Authors and 
 follow-up 
period 
 Local 
recurrence 
Metastasis Survival 
time  
Mortality   
I. Histological 
grade 
      
well --- ---  51 weeks 12% 114 Bostock 197392
intermediate --- ---  28 weeks 17%  2.5years 
poor --- --- 18 weeks 77%   
       
well --- --- Alive after 
study: 83% 
7% 83 Patnaik et al. 
198481
intermediate --- --- Alive after 
study: 44% 
56%  1500 days 
 
poor --- --- Alive after 
study: 6%  
94%   
       
well --- --- Alive after 
20 months: 
100% 
--- 75 Magnol, 
Toulemonde, 
1987139
intermediate --- --- Alive after 
20 months: 
65% 
---   
poor --- --- Alive after 
20 months: 
12% 
---   
       
well --- --- --- 9% 90 Simoes et al. 
1994126
intermediate --- --- --- 29%  601 days  
poor --- --- --- 58%   
       
well --- --- Alive after 
24 months: 
17% 
--- 120 Abadie et al. 
1999131
intermediate --- --- Alive after 
20 months: 
16% 
---  Between 12 and 
24 month 
poor --- --- Alive after 
20 months: 
1% 
---   
       
poor --- --- 1 month --- 53 Ginn et al. 
2000128
Table 3.  continued 
II. Prognostic 
indicator 
Outcome Total 
no. 
 of 
cases 
Author and 
follow-up 
period 
 Local 
recurrence 
Metastasis Survival 
time  
Mortality   
III. Invasiveness 
      
IV.  
increased --- --- increased 32 Preziosi et al. 
2004135
V.  
      
VI.  
increased --- --- increased 32 Preziosi et al. 
2007136
VII.  
      
VIII. Mitotic index 
      
0-10* --- --- 40 weeks  50 Bostock et al. 
1989124
> 10* --- --- 11 weeks increased  40 weeks 
       
9.4** yes --- --- --- 122 Simoes et al. 
 
1994126
5.5** no --- --- ---   
       
High (no cut off values)    increased 32 Preziosi et al. 
2004135
       
High (no cut off values)  not increased --- --- increased 32 Preziosi et al. 
2007136
       
> 5* --- --- 2 months (5 
months for 
grade II) 
--- 148 Romansik et 
al. 2007137
≤ 5* --- --- 70 months ---   
Table 3.  continued 
Prognostic 
indicator 
Outcome Total 
no. 
 of 
cases 
Author and 
follow-up 
period 
 Local 
recurrence 
Metastasis Median 
survival 
time 
Mortality   
IX. Nuclear 
morpholog
y 
      
        Significant difference between grade I and III and II 
and III 
24 Strefezzi et al. 
2003130
    
    
        Significant difference between grade I and III and II 
and III 
35 Maiolino et al. 
2005149 
X. AgNOR 
      
≥ 4 (≥ 4.9 for 
mortality) 
--- --- 17 weeks increased 50 Bostock et al. 
1989124
< 4 --- --- 50 weeks   40 weeks 
       
2.9 (recurrence) 
2.8 (metastasis) 
> 2.25 (mortality) 
yes yes --- increased 122 Simoes et al. 
1994126
2.2 (recurrence) 
2.3 (metastasis) 
no no ---    
       
> 1.8 --- --- --- increased 121 Scase et al. 
2006138
       
increased increased increased --- increased 56 Webster et al. 
200747
Table 3. continued 
 
XI. Prognostic 
indicator 
Outcome Total 
no. 
 of 
cases 
Author 
 Local 
recurrence 
Metastasis Survival 
time 
Mortality   
XII. Ki67 
      
> 1% --- --- --- increased 121 Scase et al. 
2006138
> 1.8 % for grade II --- --- --- increased 85  
       
< 55 / 1000 cells --- --- ---  120 Abadie et al. 
1999131
≥  55 < 135 /1000 
cells 
--- --- --- increased   
≥ 135 / 1000 cells --- --- --- increased   
≥ 93 / 1000 cells for 
grade II 
--- --- --- increased   
increased increased increased --- increased 56 Webster et al. 
200747
> 23 / 1cm2 increased increased < 24 month increased   
≤ 23 /  1cm2   > 24 month    
       
XIII. Ki67 x 
AgNOR 
      
≥ 54 increased not 
significant 
< 24 month increased 56 Webster et al. 
200747
< 54  not 
significant 
> 24 month    
XIV.  
      
XV. PCNA 
      
393.1 (recurrence) 
451.2 (metastasis) 
§§ 
no no ---  122 Simoes et al. 
1994126
875.8 (recurrence) 
976.7 (metastasis) 
> 261 (mortality)§§ 
yes yes --- increased   
Increased§ not 
significant 
not 
significant 
--- increased 56 Webster et al. 
200747
Table 3. continued 
XVI. Prognostic 
indicator 
Outcome Total 
no. 
 of 
cases 
Author 
 Local 
recurrence 
Metastasis Survival 
time 
Mortality   
 
XVII. KIT staining 
pattern 
      
II and III increased --- --- increased 98 Kiupel  et al. 
200446
       
Yes mutations associated with  grade II and III MCTs 88 Zemke et al. 
200251
    
Yes increased increased --- increased 60 Webster et al. 
200654
       
XVIII. IMVD       
> 14.1 / mm2 6 –7 month& 6 –7 month& --- increased 32 Preziosi et al. 
2004135
< 14.1 / mm2   ---    
 
Table 3.  Legend 
AgNOR: argyrophilic nucleolar organizing region counts / cell;  
Ki 67: values are given as  % of positive nuclei counted ; positive cells / 1000 cells; positive cells  / 1mm 
x1mm grid area; 
PCNA: proliferating cell nuclear antigen / 1mm x1mm grid area§; per 5 / HPF§§ 
KIT staining pattern: I) membrane-associated II) focal stippled cytoplasmic  III) diffuse cytoplasmic 
IMVD: intratumoural microvessel density / mm2
If grades are mentioned the Patnaik grading system was used;  
*   Number of mitotic figures/10 high power fields; ** Number of mitotic figures / 1000 cells  
&  No information given if local or distant recurrence  
--- No data presented, not significant or no statistical analysis given 
 
Table 4:  
Protocols Dose Frequency of administration 
VBL: 2 mg m2 i.v. Once weekly for 4 weeks,  
followed by 4 treatments every 2 weeks 
Vinblastine (VBL) / 
Prednisone112,201 
Prednisone:  
2 mg/ kg-1 p.o.  
1 mg kg-1 p.o. 
1 mg kg-1 p.o. 
 
Week 1: sid 
Week 2 +3: sid 
Thereafter: every other day 
   
VBL: 2-2.2 mg/m2 i.v. Every 3 weeks (day 1 of 21 day protocol) 
 
CTX: 200-250 mg/m2 Either p.o. over days 8-11 or i.v. on day 8 of the 
21 day protocol 
(+ furosemide 2.2 mg/kg i.v. bolus) 
 
Vinblastine / 
Cyclophosphamide 
(CTX) / Prednisone205 
Prednisone: 1 mg kg-1 
p.o. 
sid  
taper and discontinue over 24-32 weeks 
   
VBL: 2 mg/m2 i.v. Once: week 1 
 
Vinblastine / Lomustine 
(CCNU) / Prednisone 
CCNU: 70 mg/m2 p.o. Once: week 3; repeat VBL / CCNU every 2 
weeks for 6 months 
 
 
Prednisone: 0.5 mg kg-1 
p.o. 
Every other day 
   
Lomustine213  60-90 mg/m2 p.o. Once every 3 weeks, four times 
   
i.v. = intravenously; p.o. = orally; sid = once daily;  
 
 
Table 5:  
 
In case of… Drug group Example Dose 
H1 blocker Diphenhydramine 2-4mg kg-1 p.o. bid 
Rantitidine 2mg kg-1 p.o. bid H2 blocker 
Cimetidine 4mg kg-1 p.o. tid 
Suspected release of vasoactive 
substances by degranulating MCT 
Proton pump 
inhibitor 
Omeprazole 0.5-1mg kg-1 p.o. 
sid 
Evidence of gastric or duodenal 
ulceration 
Sucralfate  0.5-1g p.o. tid 
Adapted from Thamm & Vail 1999112
p.o. = orally; sid = once daily; bid = twice daily; tid = three times daily 
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